2020 is a big year for oral Korsuva.
CARA took a big hit in late 2019 from oral phase 2 data.
The second phase 3 readout for IV Korsuva, KALM-II, is set to report out in Q2 ‘20.
Cara Therapeutics focuses on developing therapies to treat itching, called pruritus, which is an unfortunate side effect for a lot of diseases. Cara’s late stage candidate, CR845 (Korsuva), initially targeted post-op pain. The company made the switch from focusing on pain to targeting pruritus after more promising data on the latter indication led the way. Cara initially focused on treating itching associated with kidney disease, but are now branching out into itching associated with other indications with their oral formulation.
You can read the full article in our deeper diligence area here. Become a free member to access the deeper diligence.